clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-12-613-622clinmed-694Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСовременные достижения и проблемы в терапии первичного гипотиреозаМodern achievement and issues in primary hypothyroidism treatmenthttps://orcid.org/0000-0002-4162-5416НиколаеваА. В.NikolaevaA. V.

Николаева Алла Витальевна — канд. мед. наук, доцент кафедры поликлинической терапии с курсами клинической фармакологии и профилактической медицины ФПК и ПП

426000, Ижевск

Alla V. Nikolaeva — Candidate of Medical Sciences, Associate Professor at the Department of Outpatient Therapy with courses in Clinical Pharmacology and Preventive Medicine, Faculty of Postgraduate Education and Professional Development

426000, Izhevsk

allavn@inbox.ruhttps://orcid.org/0000-0003-2508-7141ДударевМ. В.DudarevM. V.

Дударев Михаил Валерьевич — д-р мед. наук, профессор, заведующий кафедрой поликлинической терапии с курсами клинической фармакологии и профилактической медицины ФПК и ПП

426000, Ижевск

Mikhail V. Dudarev — Doctor of Medical Sciences, Professor, Head of the Department of Outpatient Therapy with courses in Clinical Pharmacology and Preventive Medicine, Faculty of Postgraduate Education and Professional Development

426000, Izhevsk

https://orcid.org/0000-0003-3785-5603ПименовЛ. Т.PimenovL. T.

Пименов Леонид Тимофеевич — д-р мед. наук, профессор, заведующий кафедрой врача общей практики и внутренних болезней с курсом скорой медицинской помощи ФПК и ПП

426000, Ижевск

Leonid T. Pimenov — Doctor of Medical Sciences, Professor, Head of the Department of General Practice and Internal Medicine with a course in Emergency Medical Care, Faculty of Postgraduate Education and Professional Development

426000, Izhevsk

https://orcid.org/0000-0001-7479-418XРезникЕ. В.ResnikE. V.

Резник Елена Владимировна — д-р мед. наук, заведующая кафедрой пропедевтики внутренних болезней лечебного факультета

117997, Москва

Elena V. Reznik — Doctor of Medical Sciences, Head of the Department of Propaedeutics of Internal Diseases, Faculty of Medicine

117997, Moscow

ФГБОУ ВО «Ижевская государственная медицинская академия» Минздрава РоссииРоссияIzhevsk State Medical Academy of the Ministry of Healthcare of the RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical University (Pirogov Medical University) of the Ministry of Health of the RussiaRussian Federation20232102202410112613622Copyright © Николаева А.В., Дударев М.В., Пименов Л.Т., Резник Е.В., 20242024Николаева А.В., Дударев М.В., Пименов Л.Т., Резник Е.В.Nikolaeva A.V., Dudarev M.V., Pimenov L.T., Resnik E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/694

В статье представлен обзор современных подходов и проблем в ведении пациентов с первичным гипотиреозом. В настоящее время во всем мире проводятся многочисленные доклинические и клинические исследования, направленные на совершенствование заместительной терапии и на улучшение качества жизни пациентов с первичным гипотиреозом. Целью данного обзора явился анализ мировых исследований, проведенных за последние 5 лет, и современной литературы о новых возможностях и подходах к лечению первичного гипотиреоза. Для реализации цели был проведен систематический поиск в базе данных PubMed с использованием следующих ключевых слов: «primary hypothyroidism treatment», «levothyroxine side effects», «primary hypothyroidism outcome», «new approaches to hypothyroidism therapy», «new formulations of levothyroxine», «hypothyroidism in elderly» за период с 2018 по 2023 г. На основании данного анализа удалось сделать выводы о том, что изучение различных особенностей течения заболевания и поиск новых методов лечения актуален и должен проводиться, несмотря на кажущуюся легкость в проведении заместительной терапии.

The article presents the review of the modern approaches and issues in management of the patients with primary hypothyroidism. To date globally multiple nonclinical and clinical studies designed to improve the substitutional therapy and quality of life of patients with primary hypothyroidism are performed. The objective of the review is to analyze the global studies for last 5 years and the modern literature concerning the new possibilities and approaches to the primary hypothyroidism treatment. To achieve this objective the systematic search in PubMed dataset with these key words using: "primary hypothyroidism treatment", "levothyroxine side effects", "primary hypothyroidism outcome", "new approaches to hypothyroidism therapy", "new formulations of levothyroxine", "hypothyroidism in elderly" for the period from 2018 to 2023 was performed. Based on this analysis the conclusions that the investigation of different disease course features and discovering of new treatment options are necessary despite the apparent simplicity of substitutional therapy were made.

лечение первичного гипотиреозановые лекарственные формы тироксинапобочные эффекты левотироксинаисходы первичного гипотиреозагипотиреоз у пожилыхprimary hypothyroidism treatmentlevothyroxine side effectsprimary hypothyroidism outcomenew formulations of levothyroxinehypothyroidism in elderlyReferencesТрошина Е.А., Платонова Н.М., Панфилова Е.А. Аналитический обзор результатов мониторинга основных эпидемиологических характеристик йододефицитных заболеваний у населения Российской Федерации за период 2009–2018 гг. Проблемы эндокринологии. 2021;67(2):10–19. DOI: 10.14341/probl12433Troshina E.A., Platonova N.M., Panfilova E.A. Dynamics of epidemiological indicators of thyroid pathology in the population of the Russian Federation: analytical report for the period 2009–2018. Problems of Endocrinology. 2021;67(2):10–19. (In Russian) DOI: 10.14341/probl12433Гипотиреоз: МКБ 10: Е03.1–Е03.5/Е03.8/Е03.9/Е89.0/Е06.3: Министерство Здравоохранения Российской Федерации, Российская ассоциация эндокринологов. Москва. 2021:34. Текст: электронный. Рубрикатор клинических рекомендаций МЗ РФ. URL: https://cr.minzdrav.gov.ru/recomend/531_3 (Дата обращения 25.07.2023).Hypothyroidism: IDC 10:E03.1 –Е03.5/Е03.8/ Е03.9/Е89.0/Е06.3: The Ministry of Healthcare of the Russian Federation, Russian Endocrinology Association. Moscow. 2021:34. Text: electronic. Rubrisher of clinical guidelines of the Ministry of Healthcare of the Russian Federation. URL: https://cr.minzdrav.gov.ru/recomend/531_3 (Date of reference: 25.07.2023) .Мануйлова Ю.А., Моргунова Т.Б., Фадеев В.В. Причины неэффективности заместительной терапии первичного гипотиреоза. Клиническая и экспериментальная тиреоидология. 2019;15(1):12–18. DOI: 10.14341/ket10163Manuylova Yu.A., Morgunova T.B., Fadeyev V.V. Causes of treatment failure in primary hypothyroidism. Clinical and experimental thyroidology. 2019;15(1):12–18. (In Russian) DOI: 10.14341/ket10163Virili C., Antonelli A., Santaguida M., Benvenga S., Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocrine. Review. 2019;40:118–136. DOI: 10.1210/er.2018-00168Virili C., Antonelli A., Santaguida M., Benvenga S., Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocrine. Review. 2019;40:118–136. DOI: 10.1210/er.2018-00168Freeman M.K., Adunlin G.A., Mercadel C., Danzi S., Klein I. Hypothyroid symptoms in levothyroxine-treated patients. Innovation pharmacy. 2019;10(3):10.24926/iip.v10i3.2026. DOI: 10.24926/iip.v10i3.2026Freeman M.K., Adunlin G.A., Mercadel C., Danzi S., Klein I. Hypothyroid symptoms in levothyroxine-treated patients. Innovation pharmacy. 2019;10(3):10.24926/iip.v10i3.2026. DOI: 10.24926/iip.v10i3.2026Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Notario-Pacheco B., Cobo-Cuenca A.I. Mood disorders in levothyroxine-treated hypothyroid women. Int. J. Environ. Res. Public. Health. 2019;16(23):4776. DOI: 10.3390/ijerph16234776Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Notario-Pacheco B., Cobo-Cuenca A.I. Mood disorders in levothyroxine-treated hypothyroid women. Int. J. Environ. Res. Public. Health. 2019;16(23):4776. DOI: 10.3390/ijerph16234776Ruíz-Pacheco M.G., Hernández I., Hernández-Estrella G., Basurto L., Vargas-Ortega G., González-Virla B., Molina-Ayala M., Hernández-Martínez A.F., Luengas-Mondragón R., Hernández-Allende A.A., Mendoza-Zubieta V., Balcázar-Hernández L. Severity of fatigue and its relationship with tsh before and after levothyroxine replacement therapy in patients with primary hypothyroidism. Biomedicines. 2023;11(3):811. DOI: 10.3390/biomedicines11030811Ruíz-Pacheco M.G., Hernández I., Hernández-Estrella G., Basurto L., Vargas-Ortega G., González-Virla B., Molina-Ayala M., Hernández-Martínez A.F., Luengas-Mondragón R., Hernández-Allende A.A., Mendoza-Zubieta V., Balcázar-Hernández L. Severity of fatigue and its relationship with tsh before and after levothyroxine replacement therapy in patients with primary hypothyroidism. Biomedicines. 2023;11(3):811. DOI: 10.3390/biomedicines11030811Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Laredo-Aguilera J.A., Pozuelo-Carrascosa D.P., Cobo-Cuenca A.I. Sexual function in levothyroxine-treated hypothyroid women and women without hypothyroidism: a case-control. Int. J. Environ. Res. Public. Health. 2020;17(12):4325. DOI: 10.3390/ijerph17124325Romero-Gómez B., Guerrero-Alonso P., Carmona-Torres J.M., Laredo-Aguilera J.A., Pozuelo-Carrascosa D.P., Cobo-Cuenca A.I. Sexual function in levothyroxine-treated hypothyroid women and women without hypothyroidism: a case-control. Int. J. Environ. Res. Public. Health. 2020;17(12):4325. DOI: 10.3390/ijerph17124325Jansen H.I., Boelen A., Heijboer A.C., Bruinstroop E., Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front. Endocrinol. (Lausanne). 2023;14:1130661. DOI: 10.3389/fendo.2023.1130661Jansen H.I., Boelen A., Heijboer A.C., Bruinstroop E., Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front. Endocrinol. (Lausanne). 2023;14:1130661. DOI: 10.3389/fendo.2023.1130661Cui Z., Ding X., Bian N., Chang X., Wang J., An Y., Liu J., Wang G. Relatively lower FT3 levels are associated with impaired quality of life in levothyroxine-treated patients with hashimoto thyroiditis. Int. J. Endocrinol. 2022;2022:1918674. DOI: 10.1155/2022/1918674Cui Z., Ding X., Bian N., Chang X., Wang J., An Y., Liu J., Wang G. Relatively lower FT3 levels are associated with impaired quality of life in levothyroxine-treated patients with hashimoto thyroiditis. Int. J. Endocrinol. 2022;2022:1918674. DOI: 10.1155/2022/1918674Perros P., Nagy E.V., Papini E., Van Der Feltz-Cornelis C.M., Weetman A.P., Hay H.A., Abad-Madroñero J., Tallett A.J., Bilas M., Lakwijk P., Poots A.J., Hegedüs L. Hypothyroidism and somatization: results from e-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid. 2023;3. DOI: 10.1089/thy.2022.0641Perros P., Nagy E.V., Papini E., Van Der Feltz-Cornelis C.M., Weetman A.P., Hay H.A., Abad-Madroñero J., Tallett A.J., Bilas M., Lakwijk P., Poots A.J., Hegedüs L. Hypothyroidism and somatization: results from e-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid. 2023;3. DOI: 10.1089/thy.2022.0641Groenewegen K.L., Mooij C.F., van Trotsenburg A.S.P. Persisting symptoms in patients with Hashimoto’s disease despite normal thyroid hormone levels: Does thyroid autoimmunity play a role? A systematic review. J. Transl. Autoimmun. 2021;4:100101. DOI: 10.1016/j.jtauto.2021.100101Groenewegen K.L., Mooij C.F., van Trotsenburg A.S.P. Persisting symptoms in patients with Hashimoto’s disease despite normal thyroid hormone levels: Does thyroid autoimmunity play a role? A systematic review. J. Transl. Autoimmun. 2021;4:100101. DOI: 10.1016/j.jtauto.2021.100101Perros P., Van Der Feltz-Cornelis C., Papini E., Nagy E.V., Weetman A.P., Hegedüs L. The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clin. Endocrinol. (Oxf). 2023;98(4):461–468. DOI: 10.1111/cen.14473Perros P., Van Der Feltz-Cornelis C., Papini E., Nagy E.V., Weetman A.P., Hegedüs L. The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clin. Endocrinol. (Oxf). 2023;98(4):461–468. DOI: 10.1111/cen.14473Díez J.J., Iglesias P. Control of thyroid dysfunction in spanish population registered in the primary care clinical database: an analysis of the proportion of patients with thyrotropin values outside the reference range. Horm. Metab. Res. 2023;55(3):184–190. DOI: 10.1055/a-2014-4589Díez J.J., Iglesias P. Control of thyroid dysfunction in spanish population registered in the primary care clinical database: an analysis of the proportion of patients with thyrotropin values outside the reference range. Horm. Metab. Res. 2023;55(3):184–190. DOI: 10.1055/a-2014-4589Lee K.W., Shin Y., Lee S., Lee S. Inherited disorders of thyroid hormone metabolism defect caused by the dysregulation of selenoprotein expression. Front. Endocrinol. (Lausanne). 2022;12:803024. DOI: 10.3389/fendo.2021.803024Lee K.W., Shin Y., Lee S., Lee S. Inherited disorders of thyroid hormone metabolism defect caused by the dysregulation of selenoprotein expression. Front. Endocrinol. (Lausanne). 2022;12:803024. DOI: 10.3389/fendo.2021.803024van Geest F.S., Groeneweg S., Visser W.E. Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment. Endocrine. 2021;71(3):689–695. DOI: 10.1007/s12020-020-02603-yvan Geest F.S., Groeneweg S., Visser W.E. Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment. Endocrine. 2021;71(3):689–695. DOI: 10.1007/s12020-020-02603-yPark E., Jung J., Araki O., Tsunekawa K., Park S.Y., Kim J., Murakami M., Jeong S.Y., Lee S. Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism. Sci. Rep. 2018;8(1):10090. DOI: 10.1038/s41598-018-28480-0Park E., Jung J., Araki O., Tsunekawa K., Park S.Y., Kim J., Murakami M., Jeong S.Y., Lee S. Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism. Sci. Rep. 2018;8(1):10090. DOI: 10.1038/s41598-018-28480-0Mele C., Tagliaferri M.A., Pagano L., Soranna D., Scacchi M., Aimaretti G., Biondi B., Marzullo P. Levothyroxine replacement in obese adults: the role of metabolic variables and aging on thyroid testing abnormalities. J. Clin. Endocrinol. Metab. 2019;104(12):6265–6274. DOI: 10.1210/jc.2019-00773Mele C., Tagliaferri M.A., Pagano L., Soranna D., Scacchi M., Aimaretti G., Biondi B., Marzullo P. Levothyroxine replacement in obese adults: the role of metabolic variables and aging on thyroid testing abnormalities. J. Clin. Endocrinol. Metab. 2019;104(12):6265–6274. DOI: 10.1210/jc.2019-00773Laclaustra M., Moreno-Franco B., Lou-Bonafonte J.M., Mateo-Gallego R., Casasnovas J.A., Guallar-Castillon P., Cenarro A., Civeira F. Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Diabetes Care. 2019;42(2):303–310. DOI: 10.2337/dc18-1410Laclaustra M., Moreno-Franco B., Lou-Bonafonte J.M., Mateo-Gallego R., Casasnovas J.A., Guallar-Castillon P., Cenarro A., Civeira F. Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome. Diabetes Care. 2019;42(2):303–310. DOI: 10.2337/dc18-1410Sun Y., Teng D., Zhao L., Shi X., Li Y., Shan Z., Teng W. Impaired sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subjects with subclinical hypothyroidism. Thyroid. 2022;32(4):376–384. DOI: 10.1089/ thy.2021.0500Sun Y., Teng D., Zhao L., Shi X., Li Y., Shan Z., Teng W. Impaired sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subjects with subclinical hypothyroidism. Thyroid. 2022;32(4):376–384. DOI: 10.1089/thy.2021.0500Hoermann R., Midgley J.E.M., Larisch R., Dietrich J.W. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options. Drugs Context. 2019;8:212597. DOI: 10.7573/dic.212597Hoermann R., Midgley J.E.M., Larisch R., Dietrich J.W. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options. Drugs Context. 2019;8:212597. DOI: 10.7573/dic.212597Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429Zaborek N.A., Cheng A., Imbus J.R., Long K.L., Pitt S.C., Sippel R.S, Schneider D.F. The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation. Surgery. 2019;165(1):92–98. DOI: 10.1016/j.surg.2018.04.097Zaborek N.A., Cheng A., Imbus J.R., Long K.L., Pitt S.C., Sippel R.S, Schneider D.F. The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation. Surgery. 2019;165(1):92–98. DOI: 10.1016/j.surg.2018.04.097Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429Cruz-Loya M., Chu B.B., Jonklaas J., Schneider D.F., DiStefano J. 3rd. Optimized Replacement T4 and T4+T3 Dosing in male and female hypothyroid patients with different bmis using a personalized mechanistic model of thyroid hormone regulation dynamics. Front. Endocrinol. (Lausanne). 2022;13:888429. DOI: 10.3389/fendo.2022.888429Gonzales K.M., Stan M.N., Morris J.C. 3rd., Bernet V., Castro M.R. The levothyroxine absorption test: a four-year experience (2015–2018) at The Mayo Clinic. Thyroid. 29(12):1734–1742. DOI: 10.1089/thy.2019.0256Gonzales K.M., Stan M.N., Morris J.C. 3rd., Bernet V., Castro M.R. The levothyroxine absorption test: a four-year experience (2015–2018) at The Mayo Clinic. Thyroid. 29(12):1734–1742. DOI: 10.1089/thy.2019.0256Santos Monteiro S., Santos T.S., Lopes A.M., Oliveira J.C., Freitas C., Couto Carvalho A. Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism. Endocr. Connect. 2022;11(12):e220355. DOI: 10.1530/EC-22-0355Santos Monteiro S., Santos T.S., Lopes A.M., Oliveira J.C., Freitas C., Couto Carvalho A. Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism. Endocr. Connect. 2022;11(12):e220355. DOI: 10.1530/EC-22-0355Bellastella G., Caputo M., Maiorino M.I., Longo M., Scappaticcio L., Giugliano D., Esposito K. EMPATHY: A new tool for identifying the most suitable thyroxine formulation in hypothyroid patients. Thyroid. 2019;29(7):928–933. DOI: 10.1089/thy.2018.0493Bellastella G., Caputo M., Maiorino M.I., Longo M., Scappaticcio L., Giugliano D., Esposito K. EMPATHY: A new tool for identifying the most suitable thyroxine formulation in hypothyroid patients. Thyroid. 2019;29(7):928–933. DOI: 10.1089/thy.2018.0493Tanguay M., Girard J., Scarsi C., Mautone G., Larouche R. Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin. Pharmacol. Drug Dev. 2019;8(4):521–528. DOI: 10.1002/cpdd.608Tanguay M., Girard J., Scarsi C., Mautone G., Larouche R. Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin. Pharmacol. Drug Dev. 2019;8(4):521–528. DOI: 10.1002/cpdd.608Bornikowska K., Gietka-Czernel M., Raczkiewicz D., Glinicki P., Zgliczyński W. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: an observational study. J. Clin. Med. 2021;10(22):5233. DOI: 10.3390/jcm10225233Bornikowska K., Gietka-Czernel M., Raczkiewicz D., Glinicki P., Zgliczyński W. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: an observational study. J. Clin. Med. 2021;10(22):5233. DOI: 10.3390/jcm10225233Virili C., Giovanella L., Fallahi P., Antonelli A., Santaguida M.G., Centanni M., Trimboli P. Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 2018;9:10. DOI: 10.3389/fendo.2018.00010Virili C., Giovanella L., Fallahi P., Antonelli A., Santaguida M.G., Centanni M., Trimboli P. Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 2018;9:10. DOI: 10.3389/fendo.2018.00010Cherella C.E., Wassner A.J. Update on congenital hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(1):63–69. DOI: 10.1097/MED.0000000000000520Cherella C.E., Wassner A.J. Update on congenital hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(1):63–69. DOI: 10.1097/MED.0000000000000520Guglielmi R., Grimaldi F., Negro R., Frasoldati A., Misischi I., Graziano F., Cipri C., Guastamacchia E., Triggiani V., Papini E. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord Drug. Targets. 2018;18(3):235–240. DOI: 10.2174/1871530318666180125155348Guglielmi R., Grimaldi F., Negro R., Frasoldati A., Misischi I., Graziano F., Cipri C., Guastamacchia E., Triggiani V., Papini E. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord Drug. Targets. 2018;18(3):235–240. DOI: 10.2174/1871530318666180125155348Gatta E., Bambini F., Buoso C., Gava M., Maltese V., Anelli V., Delbarba A., Pirola I., Cappelli C. Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption. Front. Endocrinol. (Lausanne). 2022;13:1080108. DOI: 10.3389/fendo.2022.1080108. PMID: 36561558; PMCID: PMC9764388Gatta E., Bambini F., Buoso C., Gava M., Maltese V., Anelli V., Del-barba A., Pirola I., Cappelli C. Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption. Front. Endocrinol. (Lausanne). 2022;13:1080108. DOI: 10.3389/fendo.2022.1080108. PMID: 36561558; PMCID: PMC9764388Markantes G.K., Dimitropoulos K., Mamali I., Tseti I., Sakellaropoulos G., Markou K.B., Michalaki M.A. Therapeutic equivalence of a new preparation of liquid levothyroxine with tablets in patients with overt primary hypothyroidism. Eur. Thyroid. J. 2021;10(1):59–64. DOI: 10.1159/000508216Markantes G.K., Dimitropoulos K., Mamali I., Tseti I., Sakellaropoulos G., Markou K.B., Michalaki M.A. Therapeutic equivalence of a new preparation of liquid levothyroxine with tablets in patients with overt primary hypothyroidism. Eur. Thyroid. J. 2021;10(1):59–64. DOI: 10.1159/000508216Fallahi P., Ferrari S.M., Elia G., Ragusa F., Paparo S.R., Antonelli A. L-T4 Therapy in enteric malabsorptive disorders. Front. Endocrinol. (Lausanne). 2021;12:626371. DOI: 10.3389/fendo.2021.626371Fallahi P., Ferrari S.M., Elia G., Ragusa F., Paparo S.R., Antonelli A. L-T4 Therapy in enteric malabsorptive disorders. Front. Endocrinol. (Lausanne). 2021;12:626371. DOI: 10.3389/fendo.2021.626371Virili C., Capriello S., Stramazzo I., Brusca N., Santaguida M.G., Gargano L., Bagaglini M.F., Bruno G., Severi C., Centanni M. Daily requirement of softgel thyroxine is independent from gastric juice pH. Front. Endocrinol. (Lausanne). 2022;13:1002583. DOI: 10.3389/fendo.2022.1002583Virili C., Capriello S., Stramazzo I., Brusca N., Santaguida M.G., Gargano L., Bagaglini M.F., Bruno G., Severi C., Centanni M. Daily requirement of softgel thyroxine is independent from gastric juice pH. Front. Endocrinol. (Lausanne). 2022;13:1002583. DOI: 10.3389/fendo.2022.1002583Liu H., Li W., Zhang W., Sun S., Chen C. Levothyroxine: conventional and novel drug delivery formulations. Endocr. Rev. 2023;44(3):393–416. DOI: 10.1210/endrev/bnac030Liu H., Li W., Zhang W., Sun S., Chen C. Levothyroxine: conventional and novel drug delivery formulations. Endocr. Rev. 2023;44(3):393–416. DOI: 10.1210/endrev/bnac030Vardarli I., Brandenburg T., Hegedüs L., Attanasio R., Nagy E., Papini E., Perros P., Weidemann F., Herrmann K., Führer D. A Questionnaire survey of german thyroidologists on the use of thyroid hormones in hypothyroid and euthyroid patients: the THESIS (treatment of hypothyroidism in europe by specialists: an international survey) collaborative. Exp. Clin. Endocrinol. Diabetes. 2022;130(9):577–586. DOI: 10.1055/a-1832-0644Vardarli I., Brandenburg T., Hegedüs L., Attanasio R., Nagy E., Papini E., Perros P., Weidemann F., Herrmann K., Führer D. A Questionnaire survey of german thyroidologists on the use of thyroid hormones in hypothyroid and euthyroid patients: the THESIS (treatment of hypothyroidism in europe by specialists: an international survey) collaborative. Exp. Clin. Endocrinol. Diabetes. 2022;130(9):577–586. DOI: 10.1055/a-1832-0644Naman A., Delemer B., Marot D., Michelet E., Decoudier B., Barraud S. Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report. Medicine (Baltimore). 2022;101(26):e29690. DOI: 10.1097/MD.0000000000029690Naman A., Delemer B., Marot D., Michelet E., Decoudier B., Barraud S. Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report. Medicine (Baltimore). 2022;101(26):e29690. DOI: 10.1097/MD.0000000000029690Ritter M.J., Gupta S., Hennessey J.V. Alternative routes of levothyroxine administration for hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(5):318–322. DOI: 10.1097/MED.0000000000000558Ritter M.J., Gupta S., Hennessey J.V. Alternative routes of levothyroxine administration for hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27(5):318–322. DOI: 10.1097/MED.0000000000000558Ghazi R.F., Al-Mayahy M.H. Levothyroxine sodium loaded dissolving microneedle arrays for transdermal delivery. ADMET DMPK. 2022;10(3):213–230. DOI: 10.5599/admet.1317Ghazi R.F., Al-Mayahy M.H. Levothyroxine sodium loaded dissolving microneedle arrays for transdermal delivery. ADMET DMPK. 2022;10(3):213–230. DOI: 10.5599/admet.1317Levothyroxine. RxList. [Electronic resource]. URL: https://www. rxlist.com/levothyroxine/generic-drug.htm (Date of reference: 09.09.2023).Levothyroxine. RxList. [Electronic resource]. URL: https://www.rxlist.com/levothyroxine/generic-drug.htm (Date of reference: 09.09.2023).L-тироксин аналоги. VIDAL. [Электронный ресурс]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/analogs (Дата обращения 09.09.2023) [L-thyroxine analogues. VIDAL. [Electronic resource]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/ analogs (Date of reference: 09.09.2023)].L-тироксин аналоги. VIDAL. [Электронный ресурс]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/analogs (Дата обращения 09.09.2023) [L-thyroxine analogues. VIDAL. [Electronic resource]. URL: https://www.vidal.ru/drugs/l-thyroxin__23557/analogs (Date of reference: 09.09.2023)].Peterson S.J., Cappola A.R., Castro M.R. et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–721. DOI: 10.1089/thy.2017.0681Peterson S.J., Cappola A.R., Castro M.R. et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–721. DOI: 10.1089/thy.2017.0681Michaelsson L.F., la Cour J.L., Medici B.B. et al. Levothyroxine/liothyronine combination therapy and quality of life: is it all about weight loss? Eur. Thyroid. J. 2018;7(5):243–250. DOI: 10.1159/000490383Michaelsson L.F., la Cour J.L., Medici B.B. et al. Levothyroxine/liothyronine combination therapy and quality of life: is it all about weight loss? Eur. Thyroid. J. 2018;7(5):243–250. DOI: 10.1159/000490383Bjerkreim B.A., Hammerstad S.S., Gulseth H.L., Berg T.J., Omdal L.J., Lee-Ødegård S., Eriksen E.F. Effect of liothyronine treatment on quality of life in female hypothyroid patients with residual symptoms on levothyroxine therapy: a randomized crossover study. Front. Endocrinol. (Lausanne). 2022;13:816566. DOI: 10.3389/fendo.2022.816566Bjerkreim B.A., Hammerstad S.S., Gulseth H.L., Berg T.J., Omdal L.J., Lee-Ødegård S., Eriksen E.F. Effect of liothyronine treatment on qua lity of life in female hypothyroid patients with residual symptoms on levothyroxine therapy: a randomized crossover study. Front. Endocrinol. (Lausanne). 2022;13:816566. DOI: 10.3389/fendo.2022.816566Hughes D.A., Skiadas K., Fitzsimmons D., Anderson P., Heald A. Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis. BMJ Open. 2021;11(12):e051702. DOI: 10.1136/bmjopen-2021-051702Hughes D.A., Skiadas K., Fitzsimmons D., Anderson P., Heald A. Liothyronine for hypothyroidism: a candidate for disinvestment or in need of further research? A value of information analysis. BMJ Open. 2021;11(12):e051702. DOI: 10.1136/bmjopen-2021-051702Latteyer S., Christoph S., Theurer S., Hönes GS., Schmid KW., Führer D., Moeller LC. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr. Relat. Cancer. 2019;26(6):565 – 574. DOI: 10.1530/ERC-18-0353Latteyer S., Christoph S., Theurer S., Hönes GS., Schmid KW., Führer D., Moeller LC. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr. Relat. Cancer. 2019;26(6):565 – 574. DOI: 10.1530/ERC-18-0353Wu C.C., Islam M.M., Nguyen P.A., Poly T.N., Wang C.H., Iqbal U., Li Y.J., Yang H.C. Risk of cancer in long-term levothyroxine users: Retrospective population-based study. Cancer. Sci. 2021;112(6):2533–2541. DOI: 10.1111/cas.14908Wu C.C., Islam M.M., Nguyen P.A., Poly T.N., Wang C.H., Iqbal U., Li Y.J., Yang H.C. Risk of cancer in long-term levothyroxine users: Retrospective population-based study. Cancer. Sci. 2021;112(6):2533–2541. DOI: 10.1111/cas.14908Alotaibe H.F., Alolaiwi L.A., Almutairi A., Alsubaie N., Badri M., Balaha M.F., Khafagy E.S., Alotaibi H.F. Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. Pharmazie. 2022;77(10):295–298. DOI: 10.1691/ph.2022.2436Alotaibe H.F., Alolaiwi L.A., Almutairi A., Alsubaie N., Badri M., Balaha M.F., Khafagy E.S., Alotaibi H.F. Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. Pharmazie. 2022;77(10):295–298. DOI: 10.1691/ph.2022.2436Lin S.Y., Lin C.L., Chen H.T., Kao C.H. Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr. Med. Res. Opin. 2018;34(5):805–812. DOI: 10.1080/03007995.2017.1378174Lin S.Y., Lin C.L., Chen H.T., Kao C.H. Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr. Med. Res. Opin. 2018;34(5):805–812. DOI: 10.1080/03007995.2017.1378174Kwak D., Ha J., Won Y., Kwon Y., Park S. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e043007. DOI: 10.1136/bmjopen-2020-043007Kwak D., Ha J., Won Y., Kwon Y., Park S. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e043007. DOI: 10.1136/bmjopen-2020-043007Ku E.J., Yoo W.S., Lee E.K., Ahn H.Y., Woo S.H., Hong J.H., Chung H.K., Park J.W. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2021;106(12):3655–3667. DOI: 10.1210/clinem/dgab539Ku E.J., Yoo W.S., Lee E.K., Ahn H.Y., Woo S.H., Hong J.H., Chung H.K., Park J.W. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2021;106(12):3655–3667. DOI: 10.1210/clinem/dgab539Yu H., Zhang W., Shen C., Zhang H., Zhang H., Zhang Y., Zou D., Gong X. Liver dysfunction induced by Levothyroxine Sodium Tablets (Euthyrox®) in a hypothyroid patient with Hashimoto’s thyroiditis: case report and literature review. Endocr. J. 2019;66(9):769–775. DOI: 10.1507/endocrj.EJ19-0078Yu H., Zhang W., Shen C., Zhang H., Zhang H., Zhang Y., Zou D., Gong X. Liver dysfunction induced by Levothyroxine Sodium Tablets (Euthyrox®) in a hypothyroid patient with Hashimoto’s thyroiditis: case report and literature review. Endocr. J. 2019;66(9):769–775. DOI: 10.1507/endocrj.EJ19-0078Einfeldt M.N., Olsen A.S., Kristensen S.L., Khalid U., Faber J., Torp-Pedersen C., Gislason G.H., Selmer C. Long-term outcome in patients with heart failure treated with levothyroxine: an observational nationwide cohort study. J. Clin. Endocrinol. Metab. 2019;104(5):1725–1734. DOI: 10.1210/jc.2018-01604Einfeldt M.N., Olsen A.S., Kristensen S.L., Khalid U., Faber J., Torp-Pedersen C., Gislason G.H., Selmer C. Long-term outcome in patients with heart failure treated with levothyroxine: an observational nationwide cohort study. J. Clin. Endocrinol. Metab. 2019;104(5):1725–1734. DOI: 10.1210/jc.2018-01604Mohajer B., Moradi K., Guermazi A., Mammen J.S.R., Hunter D.J., Roemer F.W., Demehri S. Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort. Arthritis Res. Ther. 2023;25(1):58. DOI: 10.1186/s13075-023-03012-yMohajer B., Moradi K., Guermazi A., Mammen J.S.R., Hunter D.J., Roemer F.W., Demehri S. Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort. Arthritis Res. Ther. 2023;25(1):58. DOI: 10.1186/s13075-023-03012-yNagy EV., Perros P., Papini E., Katko M., Hegedüs L. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193–201. DOI: 10.1089/thy.2020.0515Nagy EV., Perros P., Papini E., Katko M., Hegedüs L. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193–201. DOI: 10.1089/thy.2020.0515Stott D.J., Rodondi N., Kearney P.M., Ford I., Westendorp R.G.J., Mooijaart S.P., Sattar N., Aubert C.E., Aujesky D., Bauer D.C., Baumgartner C., Blum M.R., Browne J.P., Byrne S., Collet T.H., Dekkers O.M., den Elzen W.P.J., Du Puy R.S., Ellis G., Feller M., Floriani C., Hendry K., Hurley C., Jukema J.W., Kean S., Kelly M., Krebs D., Langhorne P., McCarthy G., McCarthy V., McConnachie A., McDade M., Messow M., O’Flynn A., O’Riordan D., Poortvliet R.K.E., Quinn TJ., Russell A., Sinnott C., Smit J.W.A., Van Dorland H.A., Walsh K.A., Walsh E.K., Watt T., Wilson R., Gussekloo J; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 2017;376(26):2534–2544. DOI: 10.1056/NEJMoa1603825Stott D.J., Rodondi N., Kearney P.M., Ford I., Westendorp R.G.J., Mooijaart S.P., Sattar N., Aubert C.E., Aujesky D., Bauer D.C., Baumgartner C., Blum M.R., Browne J.P., Byrne S., Collet T.H., Dekkers O.M., den Elzen W.P.J., Du Puy R.S., Ellis G., Feller M., Floriani C., Hendry K., Hurley C., Jukema J.W., Kean S., Kelly M., Krebs D., Langhorne P., McCarthy G., McCarthy V., McConnachie A., McDade M., Messow M., O’Flynn A., O’Riordan D., Poortvliet R.K.E., Quinn TJ., Russell A., Sinnott C., Smit J.W.A., Van Dorland H.A., Walsh K.A., Walsh E.K., Watt T., Wilson R., Gussekloo J; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 2017;376(26):2534–2544. DOI: 10.1056/NEJMoa1603825Gencer B., Moutzouri E., Blum M.R., Feller M., Collet T.H., Delgiovane C., da Costa B.R., Buffle E., Monney P., Gabus V., Müller H., Sykiotis G.P., Kearney P., Gussekloo J., Westendorp R., Stott D.J., Bauer D.C., Rodondi N. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am. J. Med. 2020;133(7):848–856. e5. DOI: 10.1016/j.amjmed.2020.01.018Gencer B., Moutzouri E., Blum M.R., Feller M., Collet T.H., Delgiovane C., da Costa B.R., Buffle E., Monney P., Gabus V., Müller H., Sykiotis G.P., Kearney P., Gussekloo J., Westendorp R., Stott D.J., Bauer D.C., Rodondi N. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am. J. Med. 2020;133(7):848–856. e5. DOI: 10.1016/j.amjmed.2020.01.018Zijlstra L.E., Jukema J.W., Westendorp R.G.J., Du Puy R.S., Poortvliet R.K.E., Kearney P.M., O’Keeffe L., Dekkers O.M., Blum M.R., Rodondi N., Collet T.H., Quinn T.J., Sattar N., Stott D.J., Trompet S., den Elzen W.P.J., Gussekloo J., Mooijaart S.P. Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials. Front. Endocrinol. (Lausanne). 2021;12:674841. DOI: 10.3389/fendo.2021.674841Zijlstra L.E., Jukema J.W., Westendorp R.G.J., Du Puy R.S., Poortvliet R.K.E., Kearney P.M., O’Keeffe L., Dekkers O.M., Blum M.R., Rodondi N., Collet T.H., Quinn T.J., Sattar N., Stott D.J., Trompet S., den Elzen W.P.J., Gussekloo J., Mooijaart S.P. Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials. Front. Endocrinol. (Lausanne). 2021;12:674841. DOI: 10.3389/fendo.2021.674841Wildisen L., Feller M., Del Giovane C., Moutzouri E., Du Puy R.S., Mooijaart S.P., Collet T.H., Poortvliet R.K.E., Kearney P., Quinn T.J., Klöppel S., Bauer D.C., Peeters R.P., Westendorp R., Aujesky D., Gussekloo J., Rodondi N. Effect of levothyroxine therapy on the development of depressive symptoms in older adults with subclinical hypothyroidism: an ancillary study of a randomized clinical trial. JA-MA Netw. Open. 2021;4(2):e2036645. DOI: 10.1001/jamanetworkopen.2020.36645Wildisen L., Feller M., Del Giovane C., Moutzouri E., Du Puy R.S., Mooijaart S.P., Collet T.H., Poortvliet R.K.E., Kearney P., Quinn T.J., Klöppel S., Bauer D.C., Peeters R.P., Westendorp R., Aujesky D., Gussekloo J., Rodondi N. Effect of levothyroxine therapy on the development of depressive symptoms in older adults with subclinical hypothyroidism: an ancillary study of a randomized clinical trial. JA-MA Netw. Open. 2021;4(2):e2036645. DOI: 10.1001/jamanetworkopen.2020.36645Liu Y.S., Wei M., Wang L., Liu G., Ma G.P., Ono K., Cao Z.L., Yang M., Zheng M.Q. The impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention. BMC Endocr. Disord. 2021;21(1):43. DOI: 10.1186/s12902-021-00702-zLiu Y.S., Wei M., Wang L., Liu G., Ma G.P., Ono K., Cao Z.L., Yang M., Zheng M.Q. The impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention. BMC Endocr. Disord. 2021;21(1):43. DOI: 10.1186/s12902-021-00702-zPyun J.M., Park Y.H., Kim S. Subclinical hypothyroidism and cognitive impairment. J. Alzheimers Dis. 2022;88(2):757–762. DOI: 10.3233/JAD-220302Pyun J.M., Park Y.H., Kim S. Subclinical hypothyroidism and cognitive impairment. J. Alzheimers Dis. 2022;88(2):757–762. DOI: 10.3233/JAD-220302van Vliet N.A., van Heemst D., Almeida O.P., Åsvold B.O., Aubert C.E., Bae J.B., Barnes L.E., Bauer D.C., Blauw G.J., Brayne C., Cappola A.R., Ceresini G., Comijs H.C., Dartigues J.F., Degryse J.M., Dullaart R.P.F., van Eersel M.E.A., den Elzen W.P.J., Ferrucci L., Fink H.A., Flicker L., Grabe H.J., Han J.W., Helmer C., Huisman M., Ikram M.A., Imaizumi M., de Jongh R.T., Jukema J.W., Kim K.W., Kuller L.H., Lopez O.L., Mooijaart S.P., Moon J.H., Moutzouri E., Nauck M., Parle J., Peeters R.P., Samuels M.H., Schmidt C.O., Schminke U., Slagboom P.E., Stordal E., Vaes B., Völzke H., Westendorp R.G.J., Yamada M., Yeap B.B., Rodondi N., Gussekloo J., Trompet S; Thyroid studies collaboration. association of thyroid dysfunction with cognitive function: an individual participant data analysis. JAMA Intern. Med. 2021;181(11):1440–1450. DOI: 10.1001/jamainternmed.2021.5078van Vliet N.A., van Heemst D., Almeida O.P., Åsvold B.O., Aubert C.E., Bae J.B., Barnes L.E., Bauer D.C., Blauw G.J., Brayne C., Cappola A.R., Ceresini G., Comijs H.C., Dartigues J.F., Degryse J.M., Dullaart R.P.F., van Eersel M.E.A., den Elzen W.P.J., Ferrucci L., Fink H.A., Flicker L., Grabe H.J., Han J.W., Helmer C., Huisman M., Ikram M.A., Imaizumi M., de Jongh R.T., Jukema J.W., Kim K.W., Kuller L.H., Lopez O.L., Mooijaart S.P., Moon J.H., Moutzouri E., Nauck M., Parle J., Peeters R.P., Samuels M.H., Schmidt C.O., Schminke U., Slagboom P.E., Stordal E., Vaes B., Völzke H., Westendorp R.G.J., Yamada M., Yeap B.B., Rodondi N., Gussekloo J., Trompet S; Thyroid studies collaboration. association of thyroid dysfunction with cognitive function: an individual participant data analysis. JAMA Intern. Med. 2021;181(11):1440–1450. DOI: 10.1001/jamainternmed.2021.5078Du Puy R.S., Poortvliet R.K.E., Mooijaart S.P., Stott D.J., Quinn T., Sattar N., Westendorp R.G.J., Kearney P.M., McCarthy V.J.C., Byrne S., Rodondi N., Baretella O., Collet T.H., van Heemst D., Dekkers O.M., Jukema J.W., Smit J.W.A., Gussekloo J., den Elzen W.P.J. No effect of levothyroxine on hemoglobin in older adults with subclinical hypothyroidism: pooled results from 2 randomized controlled trials. J. Clin. Endocrinol. Metab. 2022;107(6):e2339–e2347. DOI: 10.1210/clinem/dgac106Du Puy R.S., Poortvliet R.K.E., Mooijaart S.P., Stott D.J., Quinn T., Sattar N., Westendorp R.G.J., Kearney P.M., McCarthy V.J.C., Byrne S., Rodondi N., Baretella O., Collet T.H., van Heemst D., Dekkers O.M., Jukema J.W., Smit J.W.A., Gussekloo J., den Elzen W.P.J. No effect of levothyroxine on hemoglobin in older adults with subclinical hypothyroidism: pooled results from 2 randomized controlled trials. J. Clin. Endocrinol. Metab. 2022;107(6):e2339–e2347. DOI: 10.1210/clinem/dgac106Guan B., Luo J., Huang X., Tian F., Sun S., Ma Y., Yu Y., Liu R., Cao J., Fan L. Association between thyroid hormone levels and frailty in the community-dwelling oldest-old: a cross-sectional study. Chin. Med. J. (Engl). 2022;135(16):1962–1968. DOI: 10.1097/CM9.0000000000002208Guan B., Luo J., Huang X., Tian F., Sun S., Ma Y., Yu Y., Liu R., Cao J., Fan L. Association between thyroid hormone levels and frailty in the community-dwelling oldest-old: a cross-sectional study. Chin. Med. J. (Engl). 2022;135(16):1962–1968. DOI: 10.1097/CM9.0000000000002208Ravensberg A.J., Poortvliet R.K.E., Du Puy R.S., Dekkers O.M., Mooijaart S.P., Gussekloo J. Effects of discontinuation of levothyroxine treatment in older adults: protocol for a self-controlled trial. BMJ Open. 2023;13(4):e070741. DOI: 10.1136/bmjopen-2022-070741Ravensberg A.J., Poortvliet R.K.E., Du Puy R.S., Dekkers O.M., Mooijaart S.P., Gussekloo J. Effects of discontinuation of levothyroxine treatment in older adults: protocol for a self-controlled trial. BMJ Open. 2023;13(4):e070741. DOI: 10.1136/bmjopen-2022-070741

The authors declare that there are no conflicts of interest present.